513 HCC Clinical Trials Recruiting Now (May 2026): Hepatocellular Carcinoma — Immunotherapy, TACE, ADI-PEG 20, TKI

Last updated: May 19, 2026

Current Clinical Trial Landscape

Active research areas in 2026:

Immunotherapy combinations as first-line: atezo+bev (IMbrave150), durva+treme (HIMALAYA), nivo+ipi (CheckMate-9DW)
TACE + systemic therapy combinations (LEAP-012, EMERALD-1 practice-changing results)
Neoadjuvant/adjuvant immunotherapy before/after resection or transplant
Hepatic arterial infusion chemotherapy (HAIC) + immunotherapy — particularly active in China
Novel targets: ADCs, bispecific antibodies, anti-VEGF+IO combinations

Standard of care: Resectable: surgery or transplant. Intermediate (BCLC B): TACE ± systemic therapy. Advanced (BCLC C): atezolizumab + bevacizumab or durvalumab + tremelimumab first-line. Second-line: lenvatinib, sorafenib, cabozantinib, regorafenib, ramucirumab (AFP ≥400).

Recruiting Trials by Treatment Setting

Neoadjuvant / Adjuvant (Around Surgery or Transplant)

Immunotherapy before/after resection to reduce recurrence — a rapidly growing area:

Neoadjuvant:
- NCT07475026 - Neoadjuvant tislelizumab + lenvatinib in resectable HCC at high recurrence risk (Phase 3)
- NCT07461675 - Neoadjuvant immunotherapy effects on anti-tumour immunity in HCC (Phase 3)
- NCT07027436 - RT + durvalumab + tremelimumab + surgery vs surgery alone (Phase 3)
Adjuvant:
- NCT07417397 - Adjuvant TACE in HCC with high-risk recurrence factors (Phase 3)
- NCT07186621 - Adjuvant RT + sintilimab vs TACE for HCC (Phase 3)

Intermediate Stage — TACE Combinations

TACE plus systemic therapy is transforming intermediate HCC treatment after LEAP-012 and EMERALD-1 results:

- NCT06485466 - TACE + camrelizumab + apatinib for unresectable HCC (Phase 3)
- NCT07309419 - TACE + oral triple-agent cocktail vs TACE + placebo (Phase 3)
- NCT07302919 - TACE + ABCB1 inhibition vs TACE alone (Phase 3)
- NCT07322848 - DEB-TACE vs cTACE in HCC after TIPS (Phase 3)

Advanced / Metastatic — First-Line

Immunotherapy combinations are standard. Trials test new IO combos, HAIC additions, and novel agents:

IO combinations:
- NCT07490262 - IBI310 + sintilimab combination for advanced HCC (Phase 3)
- NCT06921785 - Rilvegostomig + bevacizumab ± tremelimumab (Phase 3)
- NCT06680258 - TPST-1120 + atezolizumab + bevacizumab (Phase 3)
HAIC + systemic therapy:
- NCT07267806 - Camrelizumab + apatinib ± FOLFOX chemotherapy (Phase 3)
- NCT06172205 - FOLFOX + camrelizumab + apatinib vs HAIC-FOLFOX + camrelizumab + apatinib (Phase 3)
- NCT06904170 - Durvalumab + tremelimumab ± HAIC (Phase 3)

Advanced — Second-Line and Beyond

After first-line IO failure, options include TKIs and novel agents:

- NCT07392866 - SH006 + combination therapy vs regorafenib (Phase 3)
- NCT06108272 - Livmoniplimab (anti-TIGIT) + atezolizumab + bevacizumab (Phase 3)
- NCT05317819 - ADI-PEG 20 vs placebo in high-arginine unresectable HCC (Phase 3)

Locoregional Approaches

SBRT, Y-90 radioembolization, and ablation — often combined with systemic therapy:

- NCT07293468 - SBRT vs SIRT + combination IO for unresectable HCC (Phase 3)
- NCT07166406 - Immunotherapy ± SBRT in HCC (Phase 3)
- NCT07381660 - SBRT vs surgical resection for small HCC (Phase 3)

Prevention

- NCT07529262 - AspiRe HCC: Aspirin to reduce HCC risk in cirrhosis (Phase 3)

Showing selected notable trials. View all 513 recruiting interventional trials on ClinicalTrials.gov.

Frequently Asked Questions

How do I find hepatocellular carcinoma clinical trials I'm eligible for?

Enter your HCC details into ClinTrialFinder — including Child-Pugh score, BCLC stage, AFP level, and prior treatments (TACE, sorafenib, immunotherapy). The AI matches you with trials based on your specific profile in minutes.

What liver cancer trials are currently recruiting?

There are 513 recruiting interventional trials for hepatocellular carcinoma (HCC, liver cancer) as of May 2026, including checkpoint immunotherapy combinations (atezolizumab + bevacizumab, durvalumab + tremelimumab), TACE combinations, TKI therapy (lenvatinib, cabozantinib, regorafenib), ADI-PEG 20 Phase 3 in high-arginine HCC (NCT05317819), and novel locoregional approaches.

Find HCC Trials Matched to Your Situation

Use ClinTrialFinder's AI-powered matching to find trials based on your specific condition.

Find Matching Trials